Compared to Estimates, Cinemark (CNK) Q4 Earnings: A Look at Key Metrics

Zacks Zacks Öffnen unter Zacks
Compared to Estimates, Cinemark (CNK) Q4 Earnings: A Look at Key Metrics

Cinemark Holdings (CNK) reported $776.3 million in revenue for the quarter ended December 2025, representing a year-over-year decline of 4.7%. EPS of $0.16 for the same period compares to $0.33 a year ago.

The reported revenue represents a surprise of +0.83% over the Zacks Consensus Estimate of $769.89 million. With the consensus EPS estimate being $0.24, the EPS surprise was -33.33%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Cinemark performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Average ticket price - U.S. Operating Segment: $11.03 versus the three-analyst average estimate of $11.08. Average ticket price - International Operating Segment: $3.90 versus $3.77 estimated by three analysts on average. Concession revenues per patron - U.S. Operating Segment: $8.57 versus $8.38 estimated by three analysts on average. Attendance - International Operating Segment: 14.7 million compared to the 16.75 million average estimate based on three analysts. Revenue- U.S. Operating Segment- Admissions: $326.5 million compared to the $316.91 million average estimate based on four analysts. The reported number represents a change of -3.6% year over year. Revenue- International Operating Segment- Admissions: $57.3 million versus the four-analyst average estimate of $63.73 million. The reported number represents a year-over-year change of -15.5%. Revenue- U.S. Operating Segment- Concession: $253.8 million compared to the $243.58 million average estimate based on four analysts. The reported number represents a change of -2.3% year over year. Revenue- International Operating Segment- Concession: $48.6 million compared to the $50.46 million average estimate based on four analysts. The reported number represents a change of -9.5% year over year. Total revenue- U.S.: $642.2 million versus the three-analyst average estimate of $620.37 million. The reported number represents a year-over-year change of -3.6%. Revenue- Admissions: $383.8 million versus $387.66 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -5.6% change. Revenue- Other: $90.1 million versus $85.81 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -4.6% change. Revenue- Concession: $302.4 million versus $299.37 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -3.5% change.

View all Key Company Metrics for Cinemark here>>>

Shares of Cinemark have returned +3.3% over the past month versus the Zacks S&P 500 composite's -1.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

5 Stocks Set to Double

Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Cinemark Holdings Inc (CNK): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research